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Human immunodeficiency virus type 1 (HIV-1) infection can be inhibited by small molecules that target the CCR5 coreceptor. Here, we
describe some properties of clonal viruses resistant to one such inhibitor, SCH-D, using both chimeric, infectious molecular clones and Env-
pseudotypes. Studies using combinations of CCR5 ligands, including small molecule inhibitors, monoclonal antibodies (MAbs) and chemokine
derivatives such as PSC-RANTES, show that the fully SCH-D-resistant viruses enter target cells by using the SCH-D-bound form of CCR5.
However, the way resistance to SCH-D and other small molecule CCR5 inhibitors is manifested depends on the target cell and the nature of the
assay (single- vs. multi-cycle). In multi-cycle assays using primary lymphocytes, SCH-D does not inhibit resistant molecular clones, and it can
even enhance their infectivity modestly. In contrast, the same viruses (as Env-pseudotypes) are significantly inhibited by SCH-D in single-cycle
entry assays using U87-CD4/CCR5 cells, resistance being manifested by incomplete inhibition at high SCH-D concentrations. When a single-
cycle, Env-pseudotype entry assay was performed using either U87-CD4/CCR5 cells or PBMC under comparable conditions, entry was inhibited
by up to 88% in the former cells but by only 28% in the PBMC. Hence, there are both cell- and assay-dependent influences on how resistance is
manifested. We also take this opportunity to correct our previous report that SCH-D-resistant isolates are also substantially cross-resistant to PSC-
RANTES [Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P., 2005.
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Virology 338 (1), 182–199]. A substantial element of this resistance was attributable to the unappreciated carry-over of SCH-D from the selection
cultures into analytical assays.
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A new class of drugs to treat infection with human
immunodeficiency virus type 1 (HIV-1) is now in clinical
development: the CCR5 inhibitors (Kazmierski et al., 2003;
Seibert and Sakmar, 2004; Westby and van der Ryst, 2005).
These compounds, small molecules or monoclonal antibodies
(MAbs), bind to the CCR5 coreceptor that is used in
conjunction with CD4 to mediate the fusion of HIV-1 with its⁎ Corresponding author.
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doi:10.1016/j.virol.2006.11.004target cells. By doing so, they impede the ability of the HIV-1
Env complex to interact efficiently with CCR5; the fusion
process is blocked and the viral replication cycle interrupted.
The small molecule CCR5 inhibitors are considered to act via an
allosteric mechanism involving the stabilization or induction of
a CCR5 conformation that is not efficiently recognized by the
HIV-1 Env complex (Billick et al., 2004; Dragic et al., 2000;
Kazmierski et al., 2003; Kenakin, 2004; Seibert et al., 2006;
Tsamis et al., 2003; Watson et al., 2005). Two different small
molecule CCR5 inhibitors, maraviroc (UK-427,857) and
vicriviroc (SCH-D) are now in Phase II or Phase III clinical
trials. Both compounds cause significant (∼1.5 log10) reduc-
tions in plasma viral load when administered orally to HIV-1-
infected people (Fatkenheuer et al., 2005; Schuermann et al.,
2005).
Table 1
Nomenclature and properties of viruses and env genes used in this study
Virus isolate Selecting
compound
Representative
env clone
SCH-D
resistant
CC1/85 parental isolate None CC1/85 cl.7 No
CC101.19 (Trkola et al., 2002) AD101 CC101.19 cl.7 Yes
D1/85.16 (Marozsan et al., 2005) SCH-D D1/85.16 cl.23 Yes
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selection pressure, HIV-1 develops resistance to the CCR5
small molecule inhibitors in vitro. We have shown previously
that an R5 primary isolate, CC1/85, when cultured in peripheral
blood mononuclear cells (PBMC) with either AD101 (a pre-
clinical precursor of SCH-D) or with SCH-D itself, gradually
becomes resistant to the inhibitors (see Table 1 for nomenclature
of isolates and env clones used in this study) (Marozsan et al.,
2005; Trkola et al., 2002). In general, the resistant viruses retain
the R5 phenotype, in that they continue to be dependent on
CCR5 for entry into primary CD4+ T-cells, in the presence or
absence of the inhibitor. Specifically, the replication of the
resistant viruses was efficiently inhibited by CCR5-specific
MAbs such as PA14 and 2D7 and replication of the resistant
viruses in PBMC from CCR5-Δ32 homozygotes did not occur
(Marozsan et al., 2005; Trkola et al., 2002). However, when we
studied the sensitivities of the escape mutants to the chemokine
ligands of CCR5, a more complex set of data emerged. Thus,
the AD101 escape mutant isolate, CC101.19, was only
modestly resistant to inhibition by RANTES, and the clonal
viruses bearing env genes derived from the isolate were fully
sensitive to it (Kuhmann et al., 2004; Trkola et al., 2002). In
contrast, two different SCH-D-resistant isolates were highly
cross-resistant to the chemically modified, more potent
RANTES derivative, PSC-RANTES (Marozsan et al., 2005).
This finding was unexpected because PSC-RANTES and SCH-
D bind to distinct sites on CCR5, and because PSC-RANTES is
known to down-regulate a substantial fraction of CCR5 from
the cell surface (Hartley et al., 2004). One of the virus isolates
resistant to SCH-D (D1/85.16) was able to use CXCR4 in a cell
line, but not in PBMC (Marozsan et al., 2005). However, in
general, CCR5 inhibitor escape mutants do not switch to using
CXCR4, or any other coreceptor, despite the presence of these
alternative receptors on the target cells (Marozsan et al., 2005;Table 2
Properties of selected CCR5 ligands
CCR5 ligand Type Binding site
on CCR5
Proba
HIV-1
PSC-RANTES Chemically modified
chemokine
Extracellular
loops and amino terminus
Down
CCR5
SCH-D Small molecule
(Mr =533)
TM domains Allost
gp120
PRO140 Humanized
IgG4 MAb
Extracellular
loop 2 and
amino terminus
Steric
gp120
PA12 Mouse IgG1 MAb Amino terminus Steric
gp120Trkola et al., 2002). CCR5 use must therefore be favored, even
if an inhibitory CCR5 ligand is present in the cultures.
The genetics of CCR5 inhibitor resistance are complex. The
amino acid substitutions associated with, and in some cases
proven to be causative of, resistance development are in the
gp120 subunit of the Env complex (Kuhmann et al., 2004;
Marozsan et al., 2005), which is logical given that gp120
contains the CCR5 binding site (Hartley et al., 2005). In the case
of the AD101-resistant isolate CC101.19, the amino acid
changes shown to be responsible for resistance are in the V3
region of gp120 (Kuhmann et al., 2004), an element that is
likely to form part of the CCR5 binding site (Hartley et al.,
2005; Huang et al., 2005). However, an Env-chimeric virus, D1/
85.16 cl.23, derived from the D1/85.16 isolate and resistant to
SCH-D, has no sequence changes in V3 (Marozsan et al., 2005).
Overall, then, much remains to be learned about how CCR5
inhibitor resistance develops under in vitro conditions. More-
over, there is now preliminary evidence for the evolution of
escape mutants during clinical trials of SCH-D, the resistant
viruses having phenotypic and genotypic properties that appear
to be consistent with the ones generated in vitro (Landovitz
et al., 2006).
In this study, we have investigated how the CCR5 inhibitor-
resistant viruses produced in the aforementioned studies
continue to be CCR5-dependent for entry. We studied the
properties of three clonal viruses that are isogenic outside of
their env genes. The env clone designated CC1/85 cl.7 was
isolated from the genomic DNA of cells infected with the
parental, CCR5 inhibitor-sensitive isolate CC1/85 (Table 1).
Likewise, the CC101.19 cl.7 and D1/85.16 cl.23 env genes are
from the CC101.19 and D1/85.16 isolates that were selected for
resistance to AD101 and SCH-D, respectively (Marozsan et al.,
2005; Trkola et al., 2002). By using combinations of CCR5
ligands – small molecule inhibitors, MAbs and chemokines –
we show here that the resistant viruses must have mutated to
recognize, as an entry coreceptor, the complex formed between
CCR5 and the small molecule ligands. In addition, we show that
the efficiency with which this complex promotes entry varies
with cell type, being more efficient in PBMC than in U87-CD4/
CCR5 cells. This observation has implications for the use of
engineered cell lines such as U87-CD4/CCR5 in testing for
resistance to CCR5 inhibitors (Coakley et al., 2005).ble mode of
inhibition
Interaction with
SCH-D
Interaction with
PSC-RANTES
-regulation of
from cell surface
SCH-D inhibits
PSC-RANTES induced
down-regulation
N/A
eric blockade of
-CCR5 interaction
N/A SCH-D inhibits
PSC-RANTES
induced down-regulation
blockade of
-CCR5 interaction
SCH-D partially
inhibits PRO140 binding
PSC-RANTES inhibits
PRO140 binding
blockade of
-CCR5 interaction
SCH-D does not
inhibit PA12 binding
PSC-RANTES does
not inhibit PA12 binding
Fig. 1. SCH-D is an antagonist of the PSC-RANTES induced internalization.
(A) HeLa-CD4/CCR5 cells were incubated for 1 h at 4 °C (shaded bars) or 37 °C
(open bars) with or without 300 nM PSC-RANTES. The cells were then stained
for 1 h at 4 °C with PE-labeled 3A9 or 2D7. The data shown represent the
inhibition of MAb binding after incubation with 300 nM PSC-RANTES relative
to cells stained after incubation in the absence of PSC-RANTES. The mean
values± the standard error of the mean (SEM), derived from three independent
experiments, are shown. (B) The effects of varying SCH-D concentrations on
PSC-RANTES-induced CCR5 internalization were determined. HeLa-CD4/
CCR5 cells were incubated for 1 h at 37 °C with SCH-D at the indicated
concentration before the addition of 300 nM PSC-RANTES for 1 h at 37 °C. The
cells were then stained at 4 °C for 1 h with PE-labeled 3A9. The CCR5
expression level was calculated as a percent of the specific 3A9 staining in the
same experiment under the same conditions but without PSC-RANTES
addition. The data points are the means of between 3 and 7 independent
experiments at each SCH-D concentration and are shown±SEM.
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Interactions between multiple CCR5 ligands
One way to study the properties of viruses resistant to the
small molecule CCR5 inhibitors is to assess their interactions
with other CCR5 ligands, such as chemokines and MAbs. The
various CCR5 ligands used in these studies are listed in Table
2, together with a summary of their properties, with emphasis
on whether each of them interferes with the binding of the
others.
PSC-RANTES is a chemokine derivative that has been
reported to rapidly down-regulate CCR5 from the cell surface
(Hartley et al., 2004). SCH-D is an antagonist of RANTES-
induced Ca2+ flux, guanine nucleotide exchange and chemo-
taxis mediated by CCR5 (Strizki et al., 2005). We wished to
examine how SCH-D and PSC-RANTES interacted with CCR5
when both agents were present. For example, we wanted to
determine whether SCH-D could antagonize the action of PSC-
RANTES. To carry out this study, it was first necessary to
investigate how the treatment of cells with PSC-RANTES
affected staining of the cell-surface with anti-CCR5 MAbs.
Incubation of HeLa-CD4/CCR5 (clone JC.48) cells with PSC-
RANTES (300 nM) for 1 h at 4 °C, a temperature at which
CCR5 internalization should not occur, reduced the extent of
3A9 binding by only ∼10%, compared to control cells that did
not receive PSC-RANTES (Fig. 1A). This suggests that the
binding of PSC-RANTES to CCR5 does not appreciably
occlude the 3A9 epitope by a steric mechanism. In contrast,
when the incubation with PSC-RANTES was performed at 37
°C to allow CCR5 internalization, 3A9 staining was reduced by
94%, which is consistent with the removal of CCR5 from the
cell surface at this temperature (Fig. 1A). In contrast, the
binding of MAb 2D7 was inhibited by 82% when the cells were
treated with 300 nM PSC-RANTES at either 4 °C or 37 °C
under the same conditions (Fig. 1A). This finding suggests that
the 2D7 epitope is physically occluded by PSC-RANTES
binding; indeed, the 2D7 epitope is known to overlap with the
RANTES binding site (Lee et al., 1999; Olson et al., 1999).
Together, these results show that PSC-RANTES does induce
internalization of CCR5 at 37 °C in the HeLa-CD4/CCR5 cell
line, and that this internalization can be detected by a reduction
in staining by the anti-CCR5 MAb 3A9, which binds to CCR5
in a manner that is essentially unaffected by the presence of
PSC-RANTES. SCH-D did not inhibit the binding of 3A9 or
2D7 to CCR5 (data not shown).
We next incubated HeLa-CD4/CCR5 cells with varying
concentrations of SCH-D for 1 h at 37 °C prior to the addition of
300 nM PSC-RANTES for 1 h at 37 °C. The cells were then
stained with 3A9 at 4 °C and analyzed by flow cytometry (Fig.
1B). The addition of SCH-D restored 3A9 staining to 96% of
the level seen in cells incubated with the same SCH-D
concentration, but without PSC-RANTES (Fig. 1B). This effect
of SCH-D was dose dependent, with an EC50 of 5 nM. The
simplest interpretation of the finding is that SCH-D acts to
antagonize CCR5 down-regulation by PSC-RANTES, thereby
preserving the 3A9 epitope on the cell surface.We next sought to investigate how the interactions of SCH-D
and PSC-RANTES with CCR5 affect two other CCR5 ligands,
the humanized anti-CCR5 MAb PRO 140 and the mouse anti-
CCR5 MAb PA12. The HeLa-CD4/CCR5 cells were incubated
with varying concentrations of SCH-D or PSC-RANTES for 1 h
at 4 °C prior to addition of PRO 140 or PA12, also at 4 °C. The
bound antibodies were detected with an appropriate PE- or
FITC-labeled secondary MAb. Neither SCH-D nor PSC-
RANTES inhibited PA12 binding to CCR5 in a manner that
appeared to be dose dependent, and the level of PA12 staining at
125 nM SCH-D was not significantly different from that in the
absence of SCH-D (P=0.17; paired comparison t-test for 3
independent observations) (Fig. 2A). In contrast, PSC-
Fig. 2. How SCH-D and PSC-RANTES interact with PRO 140 and PA12.
HeLa-CD4/CCR5 cells were incubated with the indicated concentrations of
SCH-D (diamonds) or PSC-RANTES (squares) for 1 h at 4 °C, and then with
25 μg/ml PA12 (A) or 30 μg/ml PRO 140 (B) at 4 °C for 1 h. Bound MAbs
were detected with a PE-labeled anti-mouse IgG1 MAb (A) or an FITC-labeled
anti-human IgG4 MAb (B). In both panels, the specific MFI values are
expressed as a percentage of those determined under the same conditions, but
in the absence of SCH-D or PSC-RANTES, and are the means of three
independent experiments±SEM.
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manner with the extent of inhibition reaching 62% at a
concentration of 125 nM (Fig. 2B). PRO 140 binding was
reduced slightly at the highest SCH-D concentration tested (by
11% at 125 nM SCH-D), and the decrease was significant
compared to control (i.e., no SCH-D) (P=0.029; paired
comparison t-test for 3 independent observations). The partial
antagonism of PRO 140 binding by SCH-D is consistent with a
recently published report which also shows that SCH-D and
PRO 140 act synergistically to inhibit infection by CCR5
inhibitor-sensitive R5 viruses (Murga et al., 2006). Hence, other
factors must be dominant over the modest interference between
these ligands at the level of CCR5 binding.
A clonal virus resistant to SCH-D is sensitive to PSC-RANTES
Our investigation of the mechanism of resistance to CCR5
inhibitors was facilitated by the use of clonal viruses produced
from plasmids containing HIV-1 env genes in a commonproviral background. In the present study, we have used three
such clonal proviruses that contain env genes cloned from the
CC1/85, CC101.19 and D1/85.16 isolates into the pNL4-3
provirus (Table 1). The Env sequences and properties of the
CC1/85 cl.7 (parental) and CC101.19 cl.7 (AD101-resistant)
viruses have been described elsewhere (Kuhmann et al., 2004).
We showed previously that CC101.19 cl.7, like the isolate from
which the env gene was cloned, was resistant to AD101 and
SCH-C, but sensitive to inhibition by RANTES and PA14, the
mouse MAb from which the humanized PRO 140 MAb was
engineered. A partial Env sequence of the D1/85.16 cl.23 virus
was published previously, and clonal viruses bearing this Env
protein were found to be highly resistant to SCH-D (Marozsan
et al., 2005). We now confirm the SCH-D resistance of the D1/
85.16 cl.23 virus and show that the AD101-resistant CC101.19
cl.7 clone is cross-resistant to SCH-D (Fig. 3A). In fact, at an
SCH-D concentration of 1 μM the replication of the CC101.19
cl.7 virus was 73% greater than that of the same virus in the
absence of SCH-D. This modest enhancement effect may be
specific to the combination of the CC101.19 cl.7 virus and the
SCH-D inhibitor, as no such increase in replication was
observed with the D1/85.16 cl.23 virus (Fig. 3A), or previously
when we studied the resistance of the CC101.19 cl.7 virus to
AD101 or SCH-C (Kuhmann et al., 2004). However, all three
clonal viruses were inhibited by PSC-RANTES with similar
IC50 values (Fig. 3D, open symbols; Table 3), and each of them
was also sensitive to the PA12 and PRO 140MAbs (Figs. 3B, C,
open symbols; Table 3). The complete sensitivity of the two
SCH-D-resistant clones to three different CCR5 ligands (a
chemokine and two MAbs) supports our contention that these
Env proteins require the CCR5 coreceptor to enter primary
CD4+ T-cells.
The D1/85.16 cl.23 clonal virus recapitulated the phenotype
of the corresponding isolate in respect of its sensitivity to the
PRO 140 MAb. We had, however, previously reported that the
SCH-D-resistant isolate D1/85.16 was cross-resistant to PSC-
RANTES in PBMC cultures (Marozsan et al., 2005), yet we
now show that the clonal virus is not. We therefore investigated
why the clone and the isolate differ in this regard.
Viruses resistant to small molecule CCR5 inhibitors use
CCR5-inhibitor complexes for infection
To further clarify how the clonal viruses interacted with
the different CCR5 ligands, we investigated what happened
when the ligands were used in combination, bearing in mind
the interactions between them that we established earlier
(Table 1). It is clear that SCH-D acts as an antagonist of both
PSC-RANTES-induced internalization of CCR5 (Fig. 1B) and
of RANTES signaling activity (Strizki et al., 2005).
Furthermore, the SCH-C small molecule ligand inhibits 125I-
RANTES binding to CCR5 (Strizki et al., 2001), and this is
also true of SCH-D (J. Strizki, personal communication). We
therefore considered it likely that SCH-D inhibits the binding
of PSC-RANTES to CCR5. Accordingly, we hypothesized
that a virus that could use the CCR5-SCH-D complex as a
coreceptor would be less affected by the addition of PSC-
Fig. 3. Effects of CCR5 inhibitors alone or in combination with SCH-D on replication of clonal viruses in PBMC. (A) PBMC were incubated with the indicated
concentration of SCH-D for 1 h at 37 °C before the addition of the CC1/85 cl.7 (squares), CC101.19 cl.7 (circles) or D1/85.16 cl.23 (triangles) clonal viruses. After
7 days of culture, the production of p24 antigen under each condition was assessed by ELISA. The results show p24 production as a percentage of that derived from
cells that were not treated with SCH-D. The values shown are the means±SEM from 6 independent experiments. (B–D) PBMCwere incubated with (closed symbols)
or without (open symbols) 1 μM SCH-D for 1 h prior to the addition of the indicated concentrations of PA12 (B), PRO 140 (C) or PSC-RANTES (D) for 1 h at 37 °C.
The CC1/85 cl.7 (squares), CC101.19 cl.7 (circles) or D1/85.16 cl.23 (triangles) clonal viruses were then added. After 7 days of culture p24 production under each
condition was assessed by ELISA. The results show p24 production as a percentage of that produced by cells infected in the absence of PA12, PRO 140 or PSC-
RANTES, but in the presence (closed symbols) or absence (open symbols) of 1 μMSCH-D. The data for CC1/85 cl.7 in the presence of 1 μMSCH-D could, therefore,
not be plotted (no p24 was produced even in the absence of another inhibitor). The addition of PA12, PRO 140 or PSC-RANTES did not reverse the lack of p24
production by CC1/85 cl.7 in the presence of 1 μM SCH-D. The values shown are the means±SEM from 6 or 7 independent experiments.
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quantities. We used the clonal CC1/85 cl.7, CC101.19 cl.7
and D1/85.16 cl.23 viruses to explore this scenario. In these
experiments, PBMC were incubated with or without 1 μM
SCH-D for 1 h prior to the addition of PA12, PRO 140 or
PSC-RANTES at various concentrations. Infection by the
wild-type CC1/85 cl.7 or the SCH-D-resistant CC101.19 cl.7
or D1/85.16 cl.23 clonal viruses was then initiated after an
additional 1 h during which the second ligand was also
present, or not (Figs. 3B–D).
In the absence of SCH-D, the CC1/85 cl.7, CC101.19 cl.7
and D1/85.16 cl.23 viruses were all similarly sensitive to both
PA12 (Fig. 3B, Table 3) and PRO 140 (Fig. 3C, Table 3). The
CCR5MAbs are therefore effective inhibitors of the viruses that
have become resistant to the small molecule CCR5 inhibitor,
which is consistent with our earlier reports using these and other
viruses and CCR5 ligands (Kuhmann et al., 2004; Marozsanet al., 2005; Trkola et al., 2002). All the clones were also
comparably sensitive to inhibition by agents not directed at
CCR5, such as T1249, CD4-IgG2 and the 2F5 monoclonal
antibody (data not shown). SCH-D (1 μM), of course,
completely inhibited replication of CC1/85 cl.7 (Fig. 3A) and
the addition of PA12 or PRO 140 at any concentration did not
reverse this inhibition (data not shown). There was no
significant effect of 1 μM SCH-D on the inhibition of D1/
85.16 cl.23 by PA12, and SCH-D caused only a slight increase
(10-fold) in the IC50 for PA12 against CC101.19 cl.7 (Fig. 3B,
Table 3). These observations are consistent with the earlier
observation that SCH-D did not significantly affect PA12
binding to CCR5 (Fig. 2A, Table 2). The addition of 1 μM
SCH-D caused a rightward shift in the dose–response curve for
PRO 140 against the SCH-D-resistant viruses CC101.19 cl.7
and D1/85.16 cl.23, leading to 43- and 18-fold increases in the
PRO 140 IC50 values, respectively (Fig. 3C, Table 3). In other
Table 3
Effect of CCR5 inhibitors alone or in combination
Ligand titrated IC50 values for clonal viruses in PBMC
CC1/85
cl.7
CC101.19
cl.7
D1/85.16
cl.23-21
SCH-D 0.82 nM >1 μM >1 μM
PA12 0.30 μg/ml 0.088 μg/ml 0.24 μg/ml
PA12 (+1 μM SCH-D) N/A a 0.84 μg/ml 0.25 μg/ml
PRO140 0.41 μg/ml 0.15 μg/ml 0.13 μg/ml
PRO140 (+1 μM SCH-D) N/A a 6.5 μg/ml 2.4 μg/ml
PSC-RANTES 0.11 nM 0.056 nM 0.17 nM
PSC-RANTES (+1 μM SCH-D) N/A a 19 nM 8.4 nM
a N/A=not applicable. Replication of the CC1/85 cl.7 virus was completely
inhibited by 1 μMSCH-D, and this inhibition was not affected by the addition of
the other CCR5 ligands.
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efficient inhibitor of the SCH-D-resistant viruses than it was in
the absence of SCH-D. This effect may arise from the modest
inhibition of PRO 140 binding to CCR5 caused by SCH-D at
high concentrations (Fig. 2B, Table 2).
A similar, but more dramatic, example of the same
phenomenon was provided by experiments involving SCH-D
and PSC-RANTES. As before, SCH-D by itself was sufficient
to inhibit the CC1/85 cl.7 wild-type virus at all PSC-RANTES
concentrations (data not shown). And, as noted above, all three
of the clonal viruses were comparably sensitive to PSC-
RANTES in the absence of SCH-D (Fig. 3D, Table 3).
However, in the presence of 1 μM SCH-D, the inhibitory
actions of PSC-RANTES against the SCH-D-resistant viruses
CC101.19 cl.7 and D1/85.16 cl.23 were substantially reversed,
with rightward shifts in the PSC-RANTES dose–response
curves of 340- and 49-fold, respectively (Fig. 3D, Table 3).
SCH-D therefore significantly antagonizes the actions of PSC-
RANTES against the SCH-D-resistant viruses, but not against
the wild-type virus.
The sensitivities of both SCH-D-resistant viruses to other
CCR5 ligands change in a similar manner when SCH-D is
also present. The IC50 values for inhibition of CC101.19 cl.7
by PA12, PRO 140 and PSC-RANTES in the presence of
1 μM SCH-D are increased by 10-, 43- and 340-fold,
respectively, relative to inhibition in the absence of SCH-D
(Table 3). The corresponding values for the D1/85.16 cl.23
virus are 1-, 18- and 49-fold (Table 3). Thus, the magnitude
of the change in sensitivity for both viruses correlates with
the ability of SCH-D to antagonize the binding or subsequent
activity of the other CCR5 ligands (Table 2). The SCH-D-
mediated reversal of PSC-RANTES-mediated inhibition of
both SCH-D-resistant viruses is substantial. As SCH-D is a
chemokine antagonist, the simplest explanation is that by
binding to CCR5, SCH-D prevents PSC-RANTES from
doing so while creating an alternative, functional binding-site
for the SCH-D-resistant viruses to use. The SCH-D-resistant
viruses must therefore be able to use CCR5-SCH-D
complexes to enter and infect PBMC, whereas wild-type
viruses can only bind to the ligand-free form of CCR5 (see
Discussion).The PSC-RANTES resistance of the D1/85.16 isolate may be
partially due to the presence of residual SCH-D in the virus
stock
The conditions under which the SCH-D-resistant isolate D1/
85.16 was generated involved the gradual escalation of the
SCH-D concentration in the cultures up to a level as high as
25 μM, which is ∼25,000-fold greater than the IC50 of the
original, SCH-D-sensitive isolate, CC1/85 (Marozsan et al.,
2005). The escape mutant isolate was routinely propagated in
the presence of 25 μM SCH-D and stocks were frozen down
from the cultures for later use, for example as the virus
inoculum in studies of cross-resistance. We showed above that
SCH-D is able to abrogate the inhibitory effects of PSC-
RANTES on two SCH-D-resistant clonal viruses. Hence, we
hypothesized that sufficient SCH-D might have been carried
over into the frozen virus stocks to make these stocks appear to
be cross-resistant to PSC-RANTES.
Too little of the original, apparently PSC-RANTES-resistant
stock of the D1/85.16 isolate remained for us to investigate this
hypothesis adequately. We therefore determined the maximum
effect that residual SCH-D could have in this experimental
system. To do this, we propagated the D1/85.16 isolate in
PBMC in the presence of 25 μM SCH-D. One day prior to
harvesting and freezing the virus stock, the SCH-D was either
thoroughly washed out or was left in the culture. The stock
containing residual SCH-D is referred to as D1/85.16(+) and
that from which the SCH-D was washed out is designated D1/
85.16(−). We then assessed the sensitivity of these stocks to
SCH-D and PSC-RANTES in PBMC-based virus replication
assays under typical conditions (Fig. 4). In these replication
cultures, the virus stock was diluted by 56-fold. Thus, if all the
added 25 μM SCH-D were carried through the propagation and
freeze-thaw of the virus stocks, the final SCH-D concentration
in the replication cultures would be ∼450 nM, sufficient to
significantly inhibit the action of PSC-RANTES (Fig. 1B).
We observed that the SCH-D resistance of the D1/85.16
isolate was essentially complete whereas the parental CC1/85
isolate was fully inhibited by SCH-D with an IC50 of 1.3 nM
(Fig. 4A), a value consistent with that one of 0.95 nM which we
had previously reported (Marozsan et al., 2005). The CC1/85
isolate was also fully sensitive to PSC-RANTES with an IC50 of
0.21 nM (Figs. 4B, C), again consistent with our previous
estimate (0.20 nM) (Marozsan et al., 2005). The D1/85.16(−)
isolate was also sensitive to inhibition by PSC-RANTES, with
>90% inhibition at a PSC-RANTES concentration of 100 nM
(Fig. 4B). However, compared to the parental CC1/85 isolate,
this virus had a slightly (2.4-fold) reduced sensitivity to PSC-
RANTES, with an IC50 value of 0.51 nM (compared to
0.21 nM). This degree of difference in IC50 values may not be
significant in this assay system, as the difference in replication
levels only reaches significance at 1 nM PSC-RANTES
(P=0.03; paired comparison t-test for 4 independent observa-
tions), and not at any other PSC-RANTES concentration. It
could arise from any SCH-D that was still carried over from the
virus-producing cultures despite the use of a washing procedure
prior to harvesting.
Fig. 4. The effect of residual SCH-D on the PSC-RANTES resistance of SCH-
D-resistant isolates. PBMC were incubated with the indicated concentration of
SCH-D (A) or PSC-RANTES (B) for 1 h at 37 °C before the addition of virus
isolates CC1/85 (diamonds) or D1/85.16 (squares). Open symbols represent D1/
85.16 isolate from which residual SCH-D had been thoroughly removed,
whereas filled symbols represent D1/85.16 isolate that was harvested in the
presence of 25 μM SCH-D. After 7 days of culture, the amount of p24 antigen
produced under each condition was assessed by ELISA. The results show p24
production as a percentage of that produced by cells infected in the absence of
any CCR5 inhibitor. The values shown are the means±SEM from 4 or 5
independent experiments.
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cultures at the time the isolates were harvested had an additional
effect on inhibition by PSC-RANTES. Thus, the IC50 value for
the D1/85.16(+) isolate (8.9 nM) was shifted by 17-fold relative
to D1/85.16(−), and D1/85.16(+) was able to replicate to 30%
of the control level (no inhibitor) when PSC-RANTES was
present at 100 nM (Fig. 4B). Similar results were obtained for
another SCH-D-resistant isolate, D101.12, that we had
previously reported to be resistant to PSC-RANTES (data not
shown) (Marozsan et al., 2005). Overall, we conclude that
residual SCH-D is substantially, but perhaps not entirely,
responsible for the high-level resistance to PSC-RANTES we
previously reported (Marozsan et al., 2005).
Assay-dependent manifestation of resistance to CCR5 inhibitors
To gain further insights into how the resistant viruses use
CCR5 for entry, we used a single-cycle infection assay to testone of the same env clones we had evaluated previously in a
multi-cycle, PBMC-based replication assay (Fig. 5). In the
PBMC assay, the env-chimeric virus bearing the Env protein
derived from the parental isolate, CC1/85 cl.7, was fully
sensitive to SCH-D (IC50=0.82 nM) as expected, whereas the
CC101.19 cl.7 virus was, again as anticipated, highly resistant
to SCH-D (Fig. 3A, Table 3). In marked contrast, luciferase-
transducing env-defective pseudotype viruses bearing the CC1/
85 cl.7 or the CC101.19 cl.7 Env proteins were all inhibited by
SCH-D in a single-cycle infection assay using U87-CD4/CCR5
target cells (Fig. 5A, Table 4). The EC50 values were similar for
both Env proteins (0.63 nM and 1.3 nM, respectively).
However, the CC101.19 cl.7 Env-pseudotyped viruses were
only partially affected by SCH-D, in that the extent of inhibition
was incomplete; at high SCH-D concentrations, the inhibition
level appears to “plateau” at 77%.
The resistance to SCH-D of the same, clonal Env protein
(CC101.19 cl.7) can therefore be manifested in two different
ways that depend upon the assay being used. The number of
variables (multi-cycle vs. single-cycle, Env-chimeric virus vs.
Env-pseudotype and PBMC vs. U87-CD4/CCR5) does, how-
ever, complicate a direct comparison. To overcome this
problem, we used a novel pseudotyping backbone that is env-
defective and transduces the humanized Renilla green fluor-
escent protein II (hrGFPII) gene under the control of the CMV
promoter, a method that allowed us to now infect PBMC with
an Env-pseudotyped virus. The backbone vector was compli-
mented with the CC1/85 cl.7 and CC101.19 cl.7 Env expression
vectors, and the resulting pseudotype stocks were used to infect
both PBMC and U87-CD4/CCR5 cells in separate cultures
under similar conditions. Infection, and its inhibition by SCH-
D, was monitored 4 days post-infection by flow cytometric
detection of hrGFPII expression. In PBMC cultures, entry of the
pseudotypes bearing the CC1/85 cl.7 Env was, as expected,
inhibited in a dose-dependent manner, with an IC50 of 1.8 nM
(Fig. 5B, Table 4). In contrast to the slight enhancement of
replication of the CC101.19 cl.7 Env-chimeric viruses by SCH-
D in PBMC (Fig. 3A), entry of the CC101.19 cl.7 hrGFPII
pseudotypes was partially inhibited, reaching an apparent
plateau at 28% inhibition. The half-maximally inhibitory
SCH-D concentration (i.e., causing 14% inhibition; EC50) was
1.4 nM, essentially the same as the IC50 value for the CC1/85
cl.7 viruses (Fig. 5B, Table 4). The CC1/85 cl.7 pseudotypes
were also efficiently inhibited by SCH-D in the U87-CD4/
CCR5 cells, with an IC50 of 0.36 nM (Fig. 5C, Table 4). Entry of
the CC101.19 cl.7 Env-pseudotypes into U87-CD4/CCR5 cells
was inhibited by SCH-D, but a plateau was again reached at
<100% inhibition, with half-maximal inhibition at 0.93 nM
(Fig. 5C, Table 4). The plateau value of 88% inhibition was
similar to that shown in Fig. 5A.
These studies show that, in single-cycle assays, SCH-D
resistance is characterized by the “plateau effect” in dose–
response curves, irrespective of whether the target cell is PBMC
or U87-CD4/CCR5 cells. However, the nature of the target cell
dramatically affects the level of the plateau. In addition, the
conditions of the assay (multi- vs. single-cycle) also play a role
in how resistance is manifested. Thus, SCH-D modestly
Fig. 5. Single-round infection assays of SCH-D sensitivity of the CC1.85 cl.7 and
CC101.19 cl.7 Envs. (A) U87-CD4/CCR5 cells were incubated with the indicated
concentration of SCH-D for 1 h at 37 °C before the addition of luciferase-transducing
viruses pseudotyped with the CC1/85 cl.7 (squares) or CC101.19 cl.7 (circles) Env
proteins. After 3 days of incubation, the cellswere assayed for luciferase activity. The
results are shown as percent inhibition where 0% inhibition is defined as the
luciferase activity in cells infected in the absence of SCH-D and 100% inhibition is
defined as the luciferase activity measured in cells that were not infected with the
pseudoviruses. The values shown are the means±SEM from 5 independent
experiments. The dashed line indicates the apparent plateau in the CC101.19 cl.7
results. (B and C) PBMC (B) or U87-CD4/CCR5 cells (C) were incubated with the
indicated concentration of SCH-D for 1 h at 37 °C before the addition of hrGFPII-
transducing viruses pseudotyped with the CC1/85 cl.7 (squares) or CC101.19 cl.7
(circles) Env proteins. After 4 days of incubation, the cells were assayed by
cytometry for hrGFPII expression. The results are shown as percent inhibition where
0% inhibition is defined as the fraction of hrGFPII+ cells in the absence of SCH-D
and 100% inhibition is defined as no hrGFPII+ cells. The values shown are the
means±SEM from 3 independent experiments. The dashed lines indicate the
apparent plateau in the CC101.19 cl.7 results.
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cl.7) in a multi-cycle assay (Fig. 3A) but instead causes a
plateau at a low level of inhibition in the same cells when a
single-cycle assay is used (Fig. 5B).
PRO 140 and SCH-D antagonism of CCR5 leads to
accumulation of CC-chemokines in PBMC cultures
SCH-D antagonizes RANTES signaling mediated by
CCR5 (Strizki et al., 2005). PA14, the parent antibody
for PRO 140, is also an antagonist of CC-chemokine
signaling through CCR5, albeit only at high concentrations
(IC50 values for MIP-1α, MIP-1β and RANTES of
∼45 μg/ml) (Olson et al., 1999). We hypothesized that
disruption of CCR5-mediated chemokine-signaling pathways
in human PBMC cultures could affect the secretion of CC-
chemokines by these cells and hence the surface expression
of CCR5. To test this, PBMC from seven anonymous
donors were mitogen stimulated for 3 days prior to
treatment for 7 days with saturating concentrations of
SCH-D (2 μM) or PRO 140 (50 μg/ml). CC-chemokine
levels in the culture supernatants were then measured (Fig.
6A). In addition, the SCH-D-treated cells were stained with
the 2D7 MAb to gauge CCR5 expression levels (Fig. 6B).
The mean MIP-1α levels were not significantly different for
the inhibitor-treated and control cells during the seven-day
period (Fig. 6A; differences of 0.9- and 1.2-fold for PRO
140 and SCH-D; P=0.30 for both compared to no
treatment). However, MIP-1β levels were significantly
elevated by both PRO 140 and SCH-D (increases of 3.6-
and 4.8-fold for PRO 140 and SCH-D; P=0.05 for both
compared to no treatment), as were RANTES levels
(increases of 2.2- and 3.9-fold for PRO 140 and SCH-D;
P=0.03 and P=0.04, respectively).
CCR5 expression on CD4+ lymphocytes from the same
donors was also significantly increased in the presence of SCH-
D (Fig. 6B). The percentage of CD4+ T-cells that were CCR5+
after 7 days of SCH-D treatment were elevated by an average of
1.5-fold compared to cells from the same donor incubated in the
absence of SCH-D (P=0.0003). The average value for the mean
fluorescence intensity of 2D7 staining on SCH-D-treated CD4+Table 4
SCH-D inhibition of pseudotype entry in PBMC and U87-CD4/CCR5 cells
env clone Reporter gene
Luciferase hrGFPII
U87-CD4/CCR5 Cell type PBMC U87-CD4/CCR5
EC50
a
(nM)
Plateau b
(%)
EC50
a
(nM)
Plateau b
(%)
EC50
a
(nM)
Plateau b
(%)
CC1/85 cl.7 0.63 100 1.8 100 0.36 100
CC101.19 cl.7 1.3 77 1.4 28 0.93 88
a The estimated concentration at which the half-maximal inhibition (half-
plateau) was reached. When the plateau is estimated to be 100%, this value is
also the IC50.
b The estimated maximum percent inhibition.
Fig. 6. Changes in CC-chemokine production from, and CCR5 expression on,
PBMC treated with CCR5 antagonists. (A) Stimulated PBMC from seven
individuals were incubated for 7 days with or without PRO 140 (50 μg/ml) or
SCH-D (2 μM) as indicated. The culture supernatants were assayed for MIP-1α
(white bars), MIP-1β (grey bars) or RANTES (black bars) content. The data
shown are the mean values±SEM for the fold-increases, compared to no
treatment, from the seven donors. (B) In the same experiment as in panel A,
stimulated PBMC from the same seven individuals were incubated for 7 days
with or without SCH-D as indicated. CD4 expression was assessed with PerCP-
labeled anti-CD4, CCR5 expression using the PE-labeled anti-CCR5MAb 2D7;
both the percentage of CD4+ T-cells that were also CCR5+ and the mean
fluorescence intensity (MFI) for the CD4+CCR5+ T-cells were determined, as
indicated. The data shown are the mean values±SEM for the fold-increases,
compared to no treatment, from the seven donors.
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(P=0.004).
Discussion
Here, we have explored the nature of HIV-1 resistance to
small molecule CCR5 inhibitors, using clonal infectious viruses
or Env-pseudotyped viruses and a variety of analytical
techniques. We previously hypothesized that there are two
general mechanisms by which HIV-1 might become resistant to
small-molecule CCR5 inhibitors while still using CCR5 for
entry, and we suggested that both mechanisms were involved
when HIV-1 CC1/85 became resistant to AD101 (Trkola et al.,
2002). Our new results are entirely consistent with this
hypothesis and help us better explain the resistance process,
as outlined below. The distinction between the two mechanisms
could be important for interpreting the evolution of resistancewhen CCR5 inhibitors are used clinically to treat HIV-1
infection (Landovitz et al., 2006).
The first mechanism, which we term “competitive
resistance”, is manifested by a change in the potency (IC50
value) of a CCR5 inhibitor (Fig. 7). In this scenario a gp120
protein would change conformation in such a way as to
increase its affinity for inhibitor-free (i.e., wild-type) CCR5.
The competitive resistance mechanism would enable a virus
to more efficiently use the lower levels of inhibitor-free
CCR5 available in the presence of a non-saturating
concentration of an inhibitor. Increasing the inhibitor
concentration would be sufficient to occupy more CCR5
receptors and thereby overcome competitive resistance.
Hence, in the face of competitive resistance, the potency of
a CCR5 inhibitor will decrease, but complete inhibition could
still be achieved if a sufficiently high concentration of
inhibitor were present, in vitro or in vivo.
In the second mechanism, which we term “noncompetitive
resistance”, a resistant virus continues to enter target cells
regardless of the concentration of the inhibitor. Noncompe-
titive resistance arises when the virus acquires the ability to
use the inhibitor-CCR5 complex for entry. When a non-
competitively resistant virus uses the inhibitor-bound form of
CCR5 less efficiently than the inhibitor-free form, the
outcome is what is often termed the “plateau effect” (i.e.,
the extent of inhibition does not increase any further once a
certain inhibitor concentration is reached, and never reaches
100%, see Fig. 5B). Under this scenario, the EC50 (the
concentration at which the inhibitor achieves 50% of its
maximal effect; i.e., half the plateau height) should be the
same as the IC50 for the action of the inhibitor against the
wild-type virus (Fig. 7). The appearance of a plateau in dose–
response curves therefore reflects the difference in the
efficiency with which the resistant virus uses the inhibitor-
free and inhibitor-bound forms of CCR5. The height of the
plateau is a measure of the magnitude of the efficiency
difference; the less efficiently the inhibitor-bound of CCR5 is
used, the higher the plateau. It therefore follows that, if entry
via the inhibitor-free and inhibitor-bound forms of CCR5
occurs with equal efficiency, any switch in entry mediated by
one receptor form to the other would not be evident in drug
titration experiments. In other words, the plateau would be at
0% inhibition and the virus would appear to be completely
resistant to the inhibitor. It follows that a combination of the
two mechanisms would result in changes in both the EC50
value and the plateau height.
We have previously demonstrated that the parental CC1/85
isolate became completely resistant to AD101 via a stepwise
accumulation of mutations in the V3 region of gp120
(Kuhmann et al., 2004; Trkola et al., 2002). The pathway
to resistance seems likely to have involved both the
competitive and noncompetitive mechanisms. Thus, an isolate
emerged after 4–6 passages in the presence of AD101 in
which a single amino acid polymorphism in V3 had
undergone purifying selection to dominance, having been
present initially at a low frequency (Kuhmann et al., 2004).
The isolate from this time point, CC101.6, was modestly
Fig. 7. Schematic depiction of possible mechanisms of resistance to an allosteric small-molecule CCR5 inhibitor. (A) CCR5 is depicted with two distinct HIV-1
interaction sites (peaks) and a separate SCH-D (or other allosteric CCR5 inhibitor) binding site (valley). The gp120 protein is depicted as having two interaction sites
that are compatible with binding to CCR5, thereby mediating infection. For convenience in drawing the figure, we depict the gp120-CCR5 interaction via one of these
sites as being weaker than the other, leaving room for a stronger interaction in panel D. This need not necessarily be the case, as the strengthened interaction in panel D
could involve both interaction sites. (B) In the presence of a high SCH-D concentration, the conformation of one of the interaction regions on CCR5 is altered,
prohibiting interaction with gp120 and preventing infection. (C) Noncompetitive resistance is depicted as a change in the conformation of gp120 to accommodate the
altered CCR5 conformation. In the case of the noncompetitive resistance described in this paper, infection through the SCH-D-free form of CCR5 is also possible for
gp120 from the SCH-D-resistant viruses we have studied here. How this form of resistance would be manifested in an entry assay at varying efficiencies of entry
through the SCH-D-CCR5 complex (relative to free CCR5) is shown below the diagram. (D) Competitive resistance is depicted as a change in the conformation of
gp120 to increase the affinity of gp120 for CCR5 (here shown by a better fit between the two). In this scenario, gp120 better competes with SCH-D for binding to
CCR5. How this form of resistance would be manifested in an entry assay with various degrees of improvement in the gp120-CCR5 interaction (relative to the wild-
type gp120) is shown below the diagram.
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compared to CC1/85 (Trkola et al., 2002). The CC101.6
isolate had a correspondingly increased ability to use low
levels of CCR5 for entry into HeLa-CD4/CCR5 cell lines
(Trkola et al., 2002). Thus, we suggest that this modest, but
perhaps clinically significant, degree of resistance is an
example of competitive resistance, arising from an increase in
the affinity of gp120 for the inhibitor-free configuration of
CCR5. The process may be similar to how R5 variants with
an apparently improved ability to “scavenge” low levels ofCCR5 are thought to emerge during the later stages of HIV-1
infection (Gorry et al., 2002; Koning et al., 2003).
When the AD101 resistance selection experiment was
continued, the further accumulation of three additional amino
acid substitutions, apparently by de novo mutation, in the V3
region led to an isolate, CC101.19, with complete resistance to
AD101 (Trkola et al., 2002). The inability of AD101 to inhibit
replication of this isolate, or clones derived from it, at even very
high concentrations (up to 20 μM; cf. IC50 of AD101 against
CC1/85 of ∼1 nM), led us to hypothesize that the resistance
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would be the use of the inhibitor-CCR5 complex for entry
(Kuhmann et al., 2004; Trkola et al., 2002).
In the present study, we have used clonal viruses and a
variety of CCR5 ligands to conclude that the fully resistant
viruses do indeed use the inhibitor-bound form of CCR5 for
entry. We studied two different clonal viruses: CC101.19 cl.7
derived from the CC101.19 isolate, and D1/85.16 cl.23, derived
from an isolate that was selected for resistance to SCH-D. We
previously reported that the CC101.19 cl.7 virus was com-
pletely resistant to AD101 and SCH-C in PBMC replication
assays and that D1/85.16 cl.23 was similarly resistant to SCH-
D. Here we confirm the SCH-D resistance of the D1/85.16 cl.23
clone and show that the replication of CC101.19 cl.7 in PBMC
is not only completely resistant to SCH-D, but is modestly
enhanced by it (Fig. 3A). Resistance of this magnitude is
strongly suggestive of a noncompetitive mechanism, with these
viruses using the SCH-D-CCR5 complex as a functional
coreceptor. The most compelling evidence that this is the case
comes from experiments in which the SCH-D-resistant clones
infect PBMC in the presence of both PSC-RANTES and SCH-
D. The opposing effect of these two CCR5 ligands, when added
together, is most logically explained if the resistant viruses can
use the CCR5-SCH-D complex.
Because our results were obtained using clonal viruses
bearing Env proteins derived from two different SCH-D-
resistant isolates generated under the selection pressures of two
different small molecule CCR5 inhibitors (AD101 and SCH-D),
we suspect they may have general relevance. Hence, the use of
the CCR5-inhibitor complex might be the predominant
mechanism for the entry of viruses fully resistant to small
molecule CCR5 inhibitors. Our general experience has been
that viruses resistant to one small molecule CCR5 inhibitor are
also cross-resistant to other members of the same inhibitor class
(TJK et al., unpublished). However, a virus resistant to
maraviroc has been reported to be sensitive to other small
molecule CCR5 inhibitors, so cross-resistance may not be a
universal phenomenon (Westby et al., 2005).
We do not yet know how the resistant viruses recognize the
inhibitor-bound configuration of CCR5. A generally accepted
model for how gp120 interacts with CCR5 is that two separate,
but topologically adjacent elements of gp120 (the V3 region and
the bridging sheet) bind to two domains on CCR5 (respectively,
the second extracellular loop and the Tyr-sulfated region of the
N-terminus) (Cormier and Dragic, 2002; Cormier et al., 2001;
Hartley et al., 2005; Huang et al., 2005; Safarian et al., 2006;
Tsamis et al., 2003). Presumably, the binding of the small
molecule inhibitor alters the geometry of CCR5 such that the
two elements of its gp120 binding site are now positioned in a
configuration that cannot be efficiently recognized by gp120
(the allosteric mechanism of inhibition at work). In the resistant
virus, however, the accumulated gp120 mutations have altered
the geometry of its own binding site such that the new
configuration of CCR5 can now be accommodated. It may be
that the sequence changes in gp120 enable the resistant virus to
now dock stably with only one element on CCR5, and not the
two required by the wild-type virus. Whether the interactionbetween V3 and the second extracellular loop or the one
between the bridging sheet and the N-terminus now dominates
the gp120-CCR5 interaction remains to be determined. By
extension, it is possible that natural isolates with relative
resistance to small molecule CCR5 inhibitors (Strizki et al.,
2001) are more dependent upon a single domain of CCR5 for
entry, so are less affected by the change in receptor conforma-
tion created by the binding of the inhibitor. Studies of clonal
viruses in single-cycle entry assays may be informative. Do
such viruses generate a plateau effect, or is the pattern of
inhibition more reflective of the competitive mechanism?
Further evidence of a noncompetitive resistance mechanism
for the CC101.19 cl.7 and D1/85.16 cl.23 viruses comes from
the use of entry assays in engineered cell lines. In both PBMC
and U87-CD4/CCR5 cells the entry of CC101.19 cl.7 Env-
pseudotyped viruses is inhibited by SCH-D in a manner that is
suggestive of noncompetitive resistance (Fig. 5). Thus, the
inhibition curves for CC101.19 cl.7 are similar to those for the
parental virus CC1/85 cl.7, except that the maximum level of
inhibition plateaus at less than 100%. As noted above, this is the
hallmark of noncompetitive resistance if the inhibitor-free and
inhibitor-bound forms of CCR5 differ in their efficiencies as
coreceptors (see Fig. 7). We conclude, therefore, that the SCH-
D resistance displayed by CC101.19 cl.7 in this system is
noncompetitive in nature, and that the efficiency with which the
SCH-D-CCR5 complex mediates the entry of this pseudovirus
is significantly lower than the efficiency with which the
inhibitor-free form of CCR5 does so.
An important conclusion of the results shown in Fig. 5 and
Table 4 is that the plateau level for the CC101.19 cl.7 Env-
pseudotypes varies by cell type. Thus, the plateau level of 28%
inhibition for the hrGFPII pseudotypes in PBMC is consider-
ably different from what occurs in U87-CD4/CCR5 cells (77%
and 88% for the luciferase and hrGFPII pseudotypes,
respectively). That these values differ implies that the efficiency
with which the CCR5-SCH-D complex mediates infection
varies between the two cell types. This, in turn, suggests that the
CCR5 coreceptor itself differs between the two cell types. There
are a variety of ways in which CCR5 might vary in a cell-type-
dependent manner: expression level, post-translational mod-
ification and subcellular localization being among them. For
example, it is possible that over-expressing CCR5 in a cell line
could affect how it is processed and post-translational modified,
creating a variety of antigenic forms on the cell surface that are
recognized with different efficiencies by wild-type and resistant
viruses, and by inhibitory ligands. Multiple antigenic forms of
CCR5 are also known to be present on PBMC (Lee et al., 1999;
Olson et al., 1999). How the presence of different amounts of
different CCR5 configurations on different cell types affects
entry and its inhibition defies rational analysis at present, for
want of hard data on what factors are relevant and to what
extent. Nonetheless, the difference between PBMC and U87-
CD4/CCR5 cells is a very real one, and one that may have
clinical significance: A single-cycle Env-pseudotype assay
based on U87-CD4/coreceptor cells (PhenoSenseTM, Mono-
gram Inc.) is now very commonly used to diagnose coreceptor
usage and the development of resistance to CCR5 inhibitors
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pseudotype, luciferase-readout assay used in Fig. 5A. Whether
an assay of this nature always generates physiologically
meaningful information is something to consider.
Whether an assay is conducted in a single-cycle or a multi-
cycle format is also relevant to how CCR5 inhibitor resistance is
manifested. Noncompetitive resistance of the CC101.19 cl.7
Env protein to SCH-D leads to a plateau effect in a single-cycle
entry assay in PBMC (Fig. 5B) but appears as modest
enhancement in a multi-cycle replication assay in the same
cells (Fig. 3A). The basis for this difference is not clear at this
time, but it is now under investigation. It is possible that the
rates and/or extents of CCR5 recycling over time influence how
single- or multi-cycle assays provide different information on
the magnitude of CCR5 inhibitor resistance. Another variable
between single- and multi-cycle assays is the long-term up-
regulation of chemokine secretion and of CCR5 expression that
is triggered by small molecule CCR5 inhibitors in the PBMC
cultures used in multi-cycle assays (Fig. 6). How an additional
CCR5 ligand such as a naturally produced chemokine would
influence the overall system cannot easily be determined, but it
is a factor that would not apply to a single-cycle assay.
Overall, the interactions between SCH-D (or other CCR5
antagonists) and PSC-RANTES (or other chemokines) and
CCR5 are rather complex. SCH-D prevents PSC-RANTES
from binding to CCR5, but also causes an increase in RANTES
and MIP-1β concentrations in the cultures (at least of lymphoid
cells) and elevates the amount of CCR5 present on the cell
surface, although almost of that receptor will be in its SCH-D-
bound form. PSC-RANTES binding to CCR5 internalizes the
receptor, but this is antagonized by SCH-D. When both SCH-D
and PSC-RANTES are present, the latter has no effect on HIV-1
entry as it is prevented from binding to CCR5 by the former.
The same scenario will, presumably, apply to the natural
RANTES andMIP-1β chemokines that accumulate over time in
PBMC cultures treated with SCH-D or other chemokine
antagonists. The increased accumulation of CC-chemokines in
the presence of a CCR5 antagonist may occur by a mechanism
similar to how PBMC from CCR5-Δ32 homozygotes secrete
higher levels of these chemokines (Dragic et al., 1996; Paxton
et al., 1996a,1996b). Thus, the failure of CCR5 to signal in
response to these chemokines may remove a feedback
mechanism that controls their constitutive secretion. The same
feedback mechanism may also influence the constitutive
expression of CCR5 in these cells, explaining the observed
up-regulation. It is not yet known if changes in circulating
chemokine levels or CCR5 expression levels occur in
individuals receiving CCR5 inhibitors for prolonged periods.
It will be of interest to address these questions because fully
understanding how the mutual interactions between the various
CCR5 ligands affect HIV-1 entry and its inhibition requires
taking all the possible variables into account.
Finally, we want to revisit an issue that arose in one of our
earlier reports (Marozsan et al., 2005). We previously showed
that the SCH-D-resistant isolates D101.12 and D1/85.16 were
cross-resistant to PSC-RANTES, a finding we confirm here. We
now believe, however, that this cross-resistance was probablysubstantially, although perhaps not completely, an unforeseen
and unappreciated consequence of the experimental conditions
we used in the original resistance selection experiments.
Specifically, the carry-over of SCH-D from the selection
cultures (in which the SCH-D concentration eventually reached
25 μM) into the frozen virus stock could have been sufficient to
influence the subsequent assays of PSC-RANTES resistance.
Thus, even after dilution of the viral inoculum into the test
cultures, the SCH-D concentration may still have been
sufficient to nearly fully occupy CCR5 and prevent PSC-
RANTES from binding. In consequence, the SCH-D-resistant
isolates appeared to be substantially cross-resistant to PSC-
RANTES when they were actually entering cells via the SCH-
D-bound conformation of CCR5 to which PSC-RANTES
cannot bind. Because these viruses can also use the inhibitor-
free form of the receptor, the presence of any carried-over SCH-
D was not suspected when we wrote our initial report (Marozsan
et al., 2005). We have now, however, shown that the SCH-D-
resistant isolates D1/85.16(−) (Fig. 4) and D101.12(−) (data not
shown) appear to be partially cross-resistant to PSC-RANTES.
Thus, in the absence of SCH-D, their IC50 values for PSC-
RANTES were increased by 2.4- and 11-fold, respectively (Fig.
4 and data not shown). The SCH-D-resistant clone D1/85.16
cl.23 is fully sensitive to PSC-RANTES. Similarly, we have
previously reported that the CC101.19 isolate acquired 10-fold
resistance to RANTES, while the clones derived from it did not
(Kuhmann et al., 2004; Trkola et al., 2002). It is possible that
this level of resistance is due to some low level of SCH-D or
AD101 that was carried through in the virus stocks, even when
due care was taken to wash the CCR5 inhibitors out of the
cultures that produced them. If this modest degree of resistance
is, in fact, a property of the viruses in the isolate, it is feasible
that the underlying resistance mechanism is competitive in
nature: i.e., an increase in the affinity of gp120 for CCR5
enables the virus to compete with PSC-RANTES more
efficiently. We have not yet studied this possibility in detail.
Formal studies of viral fitness and comparative studies will
be required to place the various escape mutants described by
ourselves and others into a suitable quantitative framework.
However, one implication of the presently available data is that
any CCR5 inhibitor-resistant viruses that emerge in vivo during
therapy might be less replication competent, and perhaps even
less pathogenic, in vivo than wild-type viruses, similar to what
has been described for Enfuvirtide-resistant viruses (Lu et al.,
2004). If escape mutants to CCR5 inhibitors are also less
replication competent than wild-type viruses in the absence of
the selecting compound, reversion to sensitivity might occur
over time after therapy is discontinued. Whether this will occur
in clinical practice remains to be determined.
Materials and methods
Cells and cell culture
HeLa-CD4/CCR5 (clone JC.48) cells were a gift of Dr.
David Kabat (Oregon Health and Science University, Portland,
OR) (Platt et al., 1998). U87-CD4/CCR5 cells (contributed by
224 P. Pugach et al. / Virology 361 (2007) 212–228Dr. HongKui Deng and Dr. Dan Littman) were obtained from
the NIH AIDS Research and Reference Reagent Program
(ARRRP) (Bjorndal et al., 1997). 293T cells were from the
American Type Culture Collection (ATCC; Manassas, VA).
HeLa-CD4/CCR5 and 293Tcells were maintained in Dulbecco's
modified Eagle medium (DMEM; Invitrogen Inc., Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS;
Invitrogen) and 100 U/ml penicillin+100 μg/ml streptomycin
(1× PenStrep; HyClone, Logan, UT). U87-CD4/CCR5 cells
were maintained in DMEM+10% FBS+1× PenStrep supple-
mented with 0.3 mg/ml G418 and 0.5 μg/ml puromycin (both
from Sigma-Aldrich, St. Louis, MO). PBMCwere purified from
leukopacks obtained from the New York Blood Center (New
York, NY) and stimulated as previously described (Kuhmann
et al., 2004). Briefly, the leukopacks were depleted of CD8+ cells
using the RosetteSep reagent (StemCell Technologies, Vancou-
ver, BC, Canada) and then purified on a Ficoll density gradient
(Kuhmann et al., 2004). Cells from each blood donor were split
into two cultures, one of which was stimulated for 3 days with
surface-immobilized anti-CD3 MAb (clone OKT3) and the
other of which was stimulated for 3 days with 5 μg/ml of
phytohemagglutinin (PHA; Sigma). All PBMC cultures were
maintained in PBMC culture medium [Rockwell Park Marine
Institute 1640 medium (RPMI 1640; Invitrogen) with 10% FBS,
1× PenStrep and 100 U/ml interleukin-2 (IL-2; ARRRP, donated
by Hoffmann-La Roche, Inc.)]. All cells were incubated at 37 °C
in a 5% CO2 atmosphere.
Antibodies and reagents
PSC-RANTES was a gift from Dr. Oliver Hartley (Centre
Medicale Universitaire, Geneva). The small molecule CCR5
inhibitor SCH-D (Tagat et al., 2004), the humanized MAb PRO
140 and the mouse MAb PA12 (Olson et al., 1999) were
donated by Dr. William Olson (Progenics Pharmaceuticals Inc,
Tarrytown, NY). PE-labeled anti-CCR5 MAbs 2D7 and 3A9
were purchased from BD-Biosciences (San Jose, CA), as were
PE-labeled anti-mouse IgG2a, PerCP-labeled anti-human CD4
and appropriate isotype controls. FITC-labeled anti-human
IgG4 MAb was purchased from Sigma (St. Louis, MO). All
restriction enzymes were from New England Biolabs (Ipswich,
MA).
Immunocytometry
HeLa-CD4/CCR5 cells were detached with versene (Invitro-
gen), transferred into Eppendorf tubes, pelleted and washed
once with culture medium prior to incubation with inhibitors or
antibodies. A total of 1×106 cells in a final volume of 1 ml were
used for each experimental condition. The cells were incubated
with CCR5 inhibitors in cytometry buffer (phosphate-buffered
saline with 10% FBS) prior to staining (the inhibitor
concentrations, temperatures and the order of addition are
stated in the text and figure legends). Staining with the
appropriate labeled antibodies, diluted according to the
manufacturer's recommendations, was carried out in cytometry
buffer at 4 °C. All cytometry was carried out using an LSRIIdigital cytometer (BD Bioscience). Because the HeLa-CD4/
CCR5 cells were cloned by limiting dilution after transduction
of CCR5 expression with a retroviral vector, they express a
stable level of CCR5 on 100% of the cells (Platt et al., 1998).
Thus, live cells were gated by forward- and side-scatter
properties, but no further gating was necessary; the mean
fluorescence intensity (MFI) of the entire live cell population
was used for further analysis. In all experiments, the MFI of
cells stained with an appropriate isotype control antibody was
used to determine a non-specific fluorescence value that was
subtracted from experimentally derived MFI values.
Staining of PBMC was performed in round-bottomed 96-
well plates. Approximately 1×106 PBMC were seeded per well
after 3 days of stimulation, and then treated for 7 days with
2 μM SCH-D in culture medium, or with culture medium only.
The cells were then pelleted in the plate and resuspended in
50 μl of PBMC FACS buffer (RPMI 1640 without phenol red
+10% FBS+0.1% NaN3). A 10-μl aliquot of each of the PE-
labeled 2D7 and PerCP-labeled anti-CD4 mAbs, or the
appropriate PE- and PerCP-labeled isotype controls, was
added to each well. The cells were incubated for 1 h at 4 °C,
then washed three times with 200 μl of PBMC FACS buffer,
resuspended in 200 μl of 2% w/v paraformaldehyde+2% w/v
sucrose in phosphate-buffered saline, then further incubated for
15 min at room temperature. A 200-μl aliquot of PBMC FACS
buffer was then added prior to flow cytometric analysis.
Plasmid construction
The pCI-env expression plasmids were constructed by
insertion of the CC1/85 cl.7 and CC101.19 cl.7 env genes
into the multiple cloning site of pCI (Promega, Madison, WI).
The env genes were amplified from the previously described
proviruses (Kuhmann et al., 2004) by PCR using PfuTurbo
polymerase (Stratagene, La Jolla, CA), according to the
manufacturer's instructions. The primers used were EcoEnv
(5′-GCGGCGGAATTCGACAGTGGCAATGAGAGT-
GAAGG-3′), which is specific for the 5′ end of the env gene
and added a unique EcoRI restriction site, and XhoNef (5′-
GCCGCCCTCGAGATACTGCTCCCACCC-3′), which over-
laps the naturally occurring XhoI restriction site in the nef gene
of these viruses. The PCR products were then cut with EcoRI
and XhoI and cloned directly into a pCI plasmid that had been
treated with the same restriction enzymes.
The pNLluc-AM vector consists of the pNL4-3 proviral
plasmid with a portion of the env gene deleted and replaced with
an SV40 promoter/firefly luciferase cassette. The construction of
the pNLluc-AM vector was accomplished by using a yeast
recombination system (Marozsan and Arts, 2003). Briefly, the
LEU2 gene was PCR-amplified using the NLleu-S (5′-
GGTGGAAATGG GGCACCATGCTCCTTGGGATATTGAT-
GATCTGTAGTCCGCGGAGATTGTACTGAGAGTGCAC-3′)
and NLleu-AS (5′-CTTTTTTCTCTCTGCACCACTC-
TTCTCTTTGCCTTGGTGGGTGCTACCTGTGCGGTATTT-
CACACCG-3′) primers. The product was then recombined into
the pRecEnv vector as described previously (Marozsan andArts,
2003) to form the pRecEnvLEU2 vector. Next, the SV40
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Control vector (Promega) using the NLluc-S (5′-GGTGG-
AAATGGGGCACCATGCTCCTTGGGATATTGAT-
GATCTGTAGTTAATGCATCTCAATTAGTCAGCAACCA-
3′) and NLluc-AS (5′-CTTTTTTCTCTCTGCACCACTCTTC
TCTTTGCCTTGGTGGGTGCTACTTACACGGCGATC-
TTTCCGCCCTTCT-3′) primers. The product was then
recombined into the pRecEnvLEU2 vector to form pRecEnv-
Luc. The HIV-Luciferase chimeric sequence from pRecEnv-
Luc was inserted into pNL4-3 using the EcoRI and XhoI
restriction sites. The final pNLluc-AM construct contains the
SV40 promoter and luciferase gene recombined into pNL4-3 at
positions 6308 to 7692. It has an in-frame stop codon in the
env gene prior to the SV40 promoter to prevent translation
through the inserted cassette. This construct leaves all the HIV-
1 genes from the NL4-3 provirus intact, with the exception of
env.
Similarly, the pNLhrGFPII plasmid consists of the pNL4-3
proviral plasmid with a portion of the env gene replaced with a
CMV promoter/hrGFPII cassette. To make this plasmid, the
env-containing EcoRI to XhoI fragment of pNL4-3 was inserted
into pBluescript II (KS+) (Stratagene) that had been cut with the
same enzymes. The resulting plasmid, pKS-NL4-3, was
digested with the restriction enzymes NdeI and BglII, as was
the plasmid phrGFPII-N (Stratagene). The fragment from
phrGFPII-N containing the CMV promoter and the hrGFPII
gene was then ligated into pKS-NL4-3 from which a fragment
of the env gene between the 3′ end of the vpu gene and the 5′
end of the Rev-response element had been removed. The EcoRI
to XhoI fragment from the resulting plasmid, pKS-NLhrGFPII,
was then subcloned back into the pNL4-3 plasmid to form
pNLhrGFPII. Similar to pNLluc-AM, this plasmid leaves all of
the HIV-1 genes intact with the exception of env. Both the
pNLluc-AM and pNLhrGFPII plasmids can be complemented
with a pCI-env expression plasmid to form pseudoviruses
capable of a single round of infection. These two pseudoviruses
transduce expression of firefly luciferase and hrGFPII reporters,
respectively.
Virus and pseudovirus stocks
The CC1/85 and D1/85.16 virus isolates were propagated in
PBMC as previously described (Trkola et al., 2002). The D1/
85.16 virus was propagated in the presence of 25 μM SCH-D.
The D1/85.16(−) virus was obtained by pelleting PBMC from
the culture medium 24 h prior to harvesting the virus stocks,
washing the cells twice in culture medium and returning them to
culture in medium lacking SCH-D. The D1/85.16(+) isolate was
propagated in the same way, except that the final culture
medium contained 25 μM SCH-D. Infectious, clonal virus
stocks were made by transfection of 293T cells with pNL4-3/
env plasmids using Lipofectamine 2000 (Invitrogen) as
previously described (Kuhmann et al., 2004). All infectious
virus stocks were filtered through a 0.45-μm filter, aliquoted
and stored at −80 °C before use. The infectious titer, measured
in 50% tissue culture infective doses (TCID50), was determined
in PBMC prior to use by standard methods (Japour et al., 1993).Pseudotyped viruses were made by cotransfection of 293T
cells with a 3:1 ratio of the plasmids pCI-env and pNLluc-AM,
or pCI-env and pNLhrGFPII, using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instructions. One
day after transfection, the cells were washed twice with culture
medium then incubated for an additional day. The pseudovirus-
containing supernatants were filtered with a 0.45-μm filter and
used immediately afterwards.
HIV-1 replication in primary cells
The assessment of HIV-1 sensitivity to entry inhibitors was
performed as described previously (Kuhmann et al., 2004;
Pugach et al., 2004). Briefly, 2×105 PBMC were seeded into
each well of a 96-well culture plate. The PBMC used in this
assay consisted of equal numbers of cells from each of the two
stimulation conditions and were derived from two or three
individuals; the cells were pelleted and resuspended in PBMC
culture medium after 3 days of stimulation as described above.
They were then treated with inhibitors as described in the text
and figure legends, the recorded concentrations of the
inhibitors taking into account the added volume of inoculum
virus. Each well of the 96-well plate was then inoculated with
100 TCID50 of the appropriate virus. The three replication-
competent clonal viruses were produced by transfection under
comparable conditions, and the titers were similar for all three.
Hence, these viruses were all used at the same dilution, and
similar quantities of p24 were therefore added to each well. For
example, the average input quantities of p24 per well in the
experiment shown in Fig. 3B were 1.7±0.3 ng/ml, 1.4±0.3 ng/
ml and 1.8±0.4 ng/ml for the CC1/85 cl.7, CC101.19 cl.7 and
D1/85 cl.23 viruses, respectively. The ensuing production of
p24 antigen was also similar; thus, in the above experiment,
the amounts of p24 produced (in the absence of PA12) were
14.1±3.5 ng/ml, 11.1±3.7 ng/ml and 10.0±3.1 ng/ml for the
same three viruses, respectively.
For the inhibitor combination assays, the cells were
incubated with SCH-D for 1 h at 37 °C prior to addition of a
second inhibitor for 1 h at 37 °C, and then the replication-
competent virus. Production of the viral p24 antigen after 7 days
of culture was quantified using an in-house ELISA (Trkola et
al., 1995). In each assay, each data point was derived from
triplicate wells. The amount of p24 produced was corrected by
subtracting the residual p24 remaining from the added virus.
The data were used only if replication in the absence of any
inhibitor produced at least 5 ng/ml of p24 (typically, the cultures
produced 10 to 20 ng/ml of p24). The results obtained using
inhibitors are expressed as a percent of control. For the single
inhibitor experiments, the control was replication in the absence
of any inhibitor; for combination experiments, the control was
replication in the presence of 1 μM SCH-D, but the absence of
any additional inhibitor.
HIV-1 entry assays
U87-CD4/CCR5 cells were seeded in white 96-well plates at
a density of 3000 cells per well in a volume of 100 μl. The
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four times the desired final concentration was added to each
well for a 1-h incubation at 37 °C. Freshly harvested
supernatants from a pCI-env/pNLluc-AM cotransfection culture
(50 μl) which contained the appropriate Env-pseudotyped
viruses were then added, and the plates were incubated for
3 days at 37 °C. At that time, 100 μl of supernatant was removed
from each well plate and was replaced with 100 μl of Bright-Glo
Luciferase Substrate (Promega). After 5 min, the plates were
analyzed in a Victor3 1420 plate-reading luminometer (Perkin
Elmer, Wellesley, MA). No background luminescence was
evident in uninfected cells. Each data point in each experiment
was derived from the average of triplicate wells. The percent
inhibition of entry was calculated by taking 100×[1− (lumtest /
lumcon)], where lumcon is the luminescence (in arbitrary RLU)
of the control infection (no inhibitor), and lumtest is the
luminescence obtained from the test condition (e.g., an inhibitor
present).
For the hrGFPII entry assays, 3×105 U87-CD4/CCR5 cells
were seeded into a 6-well plate 24 h prior to infection. On the
day of infection 2×106 PBMC consisting of equal number of
cells derived from both stimulation conditions and from two or
three donors were seeded in a 6-well plate. Both cell types were
incubated with twice the desired final SCH-D concentration in
1 ml of the appropriate culture medium for 1 h at 37 °C. A 1-ml
aliquot of freshly harvested supernatant from the appropriate
pCI-env/pNLhrGFPII transfection culture was then added, and
the cells were incubated for 4 days at 37 °C. The U87-CD4/
CCR5 cells were then lifted from the wells using trypsin
(Invitrogen) and pelleted. The PBMC were removed from the
plates and also pelleted. The cell pellets were resuspended in
1 ml of IC-Fix cell fixation buffer (Invitrogen) and incubated for
10 min at 25 °C, at which time 1 ml of cytometry buffer was
added. The cells were then assayed for hrGFPII expression by
cytometry. Gating of the U87-CD4/CCR5 cells or the
lymphocyte population from the PBMC cultures was based
on forward- and side-scatter parameters. Approximately 2×105
U87-CD4/CCR5 cells and 2×106 lymphocytes were analyzed
for each data point in each experiment. The gate for hrGFPII+
cells was set by exclusion of all events when running an
uninfected sample of the same cell type. The percent inhibition
of entry was calculated as 100×[1− (rattest / ratcon)], where ratcon
is the ratio of hrGFPII+ cells to the total cells in the control
infection (no inhibitor), and rattest is the ratio of hrGFPII
+ cells
to the total cells used in the test culture. For both entry assays,
the CC1/85 cl.7 and CC101.19 cl.7 pseudotypes were always
produced in comparable transfection cultures at the same time,
and the PBMC and U87-CD4/CCR5 cells were always tested at
the same time under comparable conditions in the hrGFPII entry
assay.
The Env-pseudotype, luciferase-readout system is a reporter
assay in which enzyme activity can be assumed to be
proportional to viral entry. In contrast, the hrGFPII pseudotypes
create a focal-infectivity assay; the cells are scored as either
being infected or not infected, based on hrGFPII expression, but
we did not assume that the intensity of hrGFPII fluorescence in
the infected cells was related to the efficiency of entry. Thereadout in each assay, luciferase activity or the fraction of
hrGFPII+ cells, was proportional to the amount of input virus
when serial dilutions were applied to U87-CD4/CCR5 cells in
the absence of an inhibitor (data not shown). This finding
validates the use of each assay to measure viral entry.
Analysis of replication and entry data
The IC50 data reported in the text and in Table 3 are based on
the data in Fig. 3. They are derived from a non-linear sigmoidal
dose–response curve fit performed in Prism (GraphPad Soft-
ware, San Diego, CA) that assumes the maximal infection level
to be 100% and the minimum to be 0%. The plateau levels
reported in the text and in Table 4 were estimated from the data
in Fig. 5, and the plateau was considered to be 100% if the
extent of inhibition at 1 μM SCH-D was not significantly
different from 100% (P≥0.05 in a paired comparison t-test). In
that scenario, the IC50 was determined as described for Table 3,
assuming 100% maximum inhibition. If, however, the extent of
inhibition at 1 μM SCH-D was significantly different from
100% (P<0.05 in a paired comparison t-test), both the plateau
level and the EC50 at which the half-plateau was reached were
determined from a non-linear sigmoidal dose–response curve fit
of the data.
Chemokine ELISA
PBMC isolated from individual donors were stimulated for
3 days, then seeded at 106 cells in 1 ml volume in 24-well plates.
The cells were incubated without treatment, with 50 μg/ml PRO
140, or with 2 μM SCH-D for 7 days before the supernatants
were collected for analysis. MIP-1α, MIP-1β and RANTES
levels were assayed using Quantikine ELISA kits (R&D
Systems, Minneapolis, MN) according to the manufacturer's
instructions.
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